Literature DB >> 20339026

Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Andreas Machens1, Henning Dralle.   

Abstract

CONTEXT: Preoperative neck ultrasonography may yield false-negative findings in more than one-third of medullary thyroid cancer (MTC) patients. If not cleared promptly, cervical lymph node metastases may emerge subsequently. Reoperations entail an excess risk of surgical morbidity and may be avoidable.
OBJECTIVE: This comprehensive investigation aimed to evaluate in a head-to-head comparison the clinical utility of pretherapeutic biomarker serum levels (basal calcitonin; stimulated calcitonin; carcinoembryonic antigen) for indicating extent of disease and providing biochemical stratification of pretherapeutic MTC risk.
DESIGN: This was a retrospective analysis.
SETTING: The setting was a tertiary referral center. PATIENTS: Included were 300 consecutive patients with previously untreated MTC.
INTERVENTIONS: The intervention was compartment-oriented surgery. MAIN OUTCOME MEASURE: Stratified biomarker levels were correlated with histopathologic extent of disease.
RESULTS: Higher biomarker levels reflected larger primary tumors and more lymph node metastases. Stratified basal calcitonin serum levels correlated better (r = 0.59) with the number of lymph node metastases than carcinoembryonic antigen (r = 0.47) or pentagastrin-stimulated calcitonin (r = 0.40) levels. Lymph node metastases were present in the ipsilateral central and lateral neck, contralateral central neck, contralateral lateral neck, and upper mediastinum, respectively, beyond basal calcitonin thresholds of 20, 50, 200, and 500 pg/ml. Bilateral compartment-oriented neck surgery achieved biochemical cure in at least half the patients with pretherapeutic basal calcitonin levels of 1,000 pg/ml or less but not in patients with levels greater than 10,000 pg/ml.
CONCLUSIONS: Most newly diagnosed MTC patients, i.e. those with pretherapeutic basal calcitonin levels greater than 200 pg/ml, may need bilateral compartment-oriented neck surgery to reduce the number of reoperations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339026     DOI: 10.1210/jc.2009-2368

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  65 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

3.  Interest of sentinel node biopsy in apparently intrathyroidal medullary thyroid cancer: a pilot study.

Authors:  M Puccini; G Manca; C Ugolini; V Candalise; A Passaretti; J Bernardini; G Boni; P Buccianti
Journal:  J Endocrinol Invest       Date:  2014-06-21       Impact factor: 4.256

4.  Increasing Importance.

Authors:  Tim Scholz
Journal:  Dtsch Arztebl Int       Date:  2017-01-09       Impact factor: 5.594

Review 5.  Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.

Authors:  C M Thomas; S L Asa; S Ezzat; A M Sawka; D Goldstein
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 6.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

7.  Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.

Authors:  Francesca Torresan; Elisabetta Cavedon; Caterina Mian; Maurizio Iacobone
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

Review 8.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

9.  Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma.

Authors:  Philip M Spanheimer; Ian Ganly; Joanne Chou; Marinela Capanu; Ronald A Ghossein; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Brian R Untch
Journal:  Ann Surg Oncol       Date:  2019-09-23       Impact factor: 5.344

10.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.